# OnCo record k36-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/k36-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "k36-therapeutics" ;
  schema:name "K36 Therapeutics"@en ;
  schema:description "K36 Therapeutics makes pills that block an enzyme called NSD2 (also known as MMSET), which is overactive in about one in five multiple myeloma cases because of a chromosome swap. It is also testing the approach in prostate cancer."@en ;
  schema:url <https://onco.cc/companies/k36-therapeutics/>, <https://www.k36tx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.k36tx.com/>, <https://www.prnewswire.com/news-releases/k36-therapeutics-launches-with-30-million-series-a-financing-from-f-prime-capital-and-atlas-venture-with-eight-roads-ventures-301440553.html>, <https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/epigenetics/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> .